As Europe’s emerging legal medical cannabis industry continues to expand, the market is becoming more accepted and mainstream. A recent example of this is Medios AG’s entry into the medical cannabis market through an announced partnership with Bedrocan International BV.

“The Medios Group (“Medios” or “the Company”), a leading provider of specialty pharmaceuticals in Europe, is expanding its product portfolio and entering the medicinal cannabis market. To this end, Medios is partnering with the Dutch company Bedrocan International BV (“Bedrocan”), a leading international manufacturer of pharmaceutical-grade medicinal cannabis. Medios has secured exclusive distribution rights for Bedrocan products in Germany, Spain, Belgium, Italy, and Austria.” the companies stated in an industry news release.

“The agreement initially covers medicinal cannabis from Bedrocan’s EU-GMP-certified production facility in Denmark and will be extended to include products from other Bedrocan production facilities starting January 1, 2027.” the companies added. “The partnership is currently focused on the German market and will be gradually expanded to other EU countries over the next two years. It builds on Medios’ long-standing presence in the German and EU pharmacy market and its expertise in GDP-certified pharmaceutical logistics. Cannaflos, the “Gesellschaft für medizinisches Cannabis mbH” (Medical Cannabis Company), supports Medios as a distribution partner in Germany.”

“By entering the medicinal cannabis market, we are expanding our portfolio to include a product that can play an important role for numerous patients with chronic and serious illnesses. Cannabis offers a valuable addition to therapy, particularly in the fields of oncology and neurology.” said Constantijn van Rietschoten, member of the board of Medios AG.

“Medical cannabis is currently used, among other things, to alleviate pain, nausea, and loss of appetite in patients, for example, as part of cancer therapies. With the expansion of its product portfolio, Medios is specifically strengthening its expertise in oncology and neurology, as well as in other areas of indication where supportive treatments are required. This step underscores Medios’ positioning as a comprehensive partner for patient-specific therapies.” Medios wrote about the strategic importance of the announced partnership for the company.

“From the very beginning, our cannabis has been exclusively intended for patients or drug developers. This pharmaceutical approach has allowed us to connect with a reputable pharmaceutical distributor like Medios. We are therefore thrilled to have found a reliable and solid distribution partner to get our products to German patients.” Bedrocan’s CEO Jaap Erkelens explained. “With this collaboration, we are introducing a one-stop-shop for pharmacists to place their orders. They no longer have to visit dozens of distributors in their search for Bedrocan’s cannabis.”

Germany is currently home to the largest legal medical cannabis market in Europe. Beau Whitney, founder of Whitney Economics, published data last year that estimated Germany’s legal medical cannabis patient base to be as much as 900,000 patients.

Legal medical cannabis sales first launched in German pharmacies in 2017. Since the initial launch of sales, safe access to medical cannabis via Germany’s pharmacies has increased dramatically, as demonstrated by statistics that were included in a newsletter published by the German Cannabis Business Association (BvCW) last year.

“Patients can order cannabis online with a private prescription and have it delivered to their home. Nationwide, around 2,500 of the 17,000 pharmacies now offer medical cannabis,” BvCW stated at the time (translated from German to English). “The industry’s revenue is now estimated at around half a billion euros.”

“In Germany, an increasing number of patients are benefiting from access to medical cannabis. Medios focuses specifically on the reimbursable segment of medical cannabis, thereby ensuring independence from potential legal changes in the self-pay market. As a pioneer in this market, Bedrocan has established a trusted and strong position, as many patients rely on the constant availability of high-quality medical cannabis. With its entry into the reimbursable medical cannabis market and the strategic partnership with Bedrocan, Medios is positioning itself as a key player in this important and growing sector in Germany.” Medios stated.

***

About Bedrocan

Bedrocan is the leading manufacturer of pharmaceutical-grade medical cannabis. For over 20 years, Bedrocan has specialized in the production of cannabis as a pharmaceutical active ingredient (API) in accordance with EU-GMP standards. Bedrocan prioritizes providing medical cannabis with a consistent cannabinoid profile and adheres to defined pharmaceutical specifications. This commitment to consistency and reliability enables trustworthy and reproducible therapy for patients. Bedrocan supplies regulatory authorities and partners in numerous countries and, with its scientifically sound approach, makes a significant contribution to the professionalization of the medical cannabis market.

About Medios AG

Medios is a leading provider of specialty pharmaceuticals in Europe. With locations in Germany, the Netherlands, Belgium, and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios focuses on future-oriented personalized medicine to make the most innovative therapies available to everyone, in collaboration with pharmacies, medical practices, and pharmaceutical companies.

Medios AG is Germany’s first publicly listed specialty pharma company. Its shares (ISIN: DE000A1MMCC8) are traded on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.